PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 62.3092

Change

0.00 (0.00)%

Market Cap

N/A

Volume

8.12K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-17 )

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.34% 29% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.34% 29% F 22% F
Trailing 12 Months  
Capital Gain -3.55% 57% F 34% F
Dividend Return 0.01% 6% D- N/A F
Total Return -3.53% 57% F 27% F
Trailing 5 Years  
Capital Gain 6.62% 43% F 36% F
Dividend Return 0.08% 5% F N/A F
Total Return 6.70% 43% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 1.82% 52% F 44% F
Dividend Return 1.84% 48% F 33% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 16.33% 57% F 60% D-
Risk Adjusted Return 11.26% 52% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.